These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 16236860)
21. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762 [TBL] [Abstract][Full Text] [Related]
22. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Ambrose PG; Anon JB; Bhavnani SM; Okusanya OO; Jones RN; Paglia MR; Kahn J; Drusano GL Diagn Microbiol Infect Dis; 2008 May; 61(1):13-20. PubMed ID: 18313879 [TBL] [Abstract][Full Text] [Related]
23. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. Benko R; Matuz M; Doro P; Peto Z; Molnar A; Hajdu E; Nagy E; Gardi J; Soos G Int J Antimicrob Agents; 2007 Aug; 30(2):162-8. PubMed ID: 17570646 [TBL] [Abstract][Full Text] [Related]
25. Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. Goudah A; Abo El-Sooud K; Shim JH; Shin HC; Abd El-Aty AM J Vet Pharmacol Ther; 2008 Oct; 31(5):399-405. PubMed ID: 19000258 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825 [TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Murillo O; Doménech A; Garcia A; Tubau F; Cabellos C; Gudiol F; Ariza J Antimicrob Agents Chemother; 2006 Dec; 50(12):4011-7. PubMed ID: 17015630 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. Aboubakr M Br Poult Sci; 2012; 53(6):784-9. PubMed ID: 23398423 [TBL] [Abstract][Full Text] [Related]
30. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Grossman RF; Ambrusz ME; Fisher AC; Khashab MM; Kahn JB Clin Ther; 2006 Aug; 28(8):1175-1180. PubMed ID: 16982294 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619 [TBL] [Abstract][Full Text] [Related]
32. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Schafer J; Hovde LB; Simonson D; Rotschafer JC Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998 [TBL] [Abstract][Full Text] [Related]
33. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Noreddin AM; Hoban DJ; Zhanel GG Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101 [TBL] [Abstract][Full Text] [Related]
34. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Deguchi T; Nakane K; Yasuda M; Shimizu T; Monden K; Arakawa S; Matsumoto T Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636 [TBL] [Abstract][Full Text] [Related]
35. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections]. Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940 [TBL] [Abstract][Full Text] [Related]
36. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363 [TBL] [Abstract][Full Text] [Related]
37. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296 [TBL] [Abstract][Full Text] [Related]
38. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Martinez FJ; Grossman RF; Zadeikis N; Fisher AC; Walker K; Ambruzs ME; Tennenberg AM Eur Respir J; 2005 Jun; 25(6):1001-10. PubMed ID: 15929954 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. Meinl B; Hyatt JM; Forrest A; Chodosh S; Schentag JJ Int J Antimicrob Agents; 2000 Nov; 16(3):273-80. PubMed ID: 11091047 [TBL] [Abstract][Full Text] [Related]
40. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Hutschala D; Skhirtladze K; Zuckermann A; Wisser W; Jaksch P; Mayer-Helm BX; Burgmann H; Wolner E; Müller M; Tschernko EM Antimicrob Agents Chemother; 2005 Dec; 49(12):5107-11. PubMed ID: 16304179 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]